Completed PHASE3 INTERVENTIONAL 2-arm NCT02246127

Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor (SEQTOR)

Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)

Sponsor: European Neuroendocrine Tumor Society

Conditions Neuroendocrine Tumors

Interventions Drug: Everolimus STZ-5FU

Updated 12 times since 2017 Last updated: May 9, 2025 Started: Oct 27, 2014 Primary completion: Nov 18, 2020 Completion: Jul 12, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Neuroendocrine Tumors and is currently completed. European Neuroendocrine Tumor Society leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Jun 2025 — Sep 2025 [monthly]

Completed PHASE3
Sep 2024 — Jun 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed

▶ Show 7 earlier versions

Apr 2022 — Mar 2023 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Apr 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2019 — Apr 2020 [monthly]

Recruiting PHASE3
Jun 2018 — May 2019 [monthly]

Recruiting PHASE3
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Jun 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Neuroendocrine Tumor Society
Grupo Espanol de Tumores Neuroendocrinos
Kantar Health
Novartis Pharmaceuticals

Data source: Grupo Espanol de Tumores Neuroendocrinos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Amsterdam, Netherlands , Angers, France , Bad Berka, Germany , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Brest, France , Clichy, France and 25 more locations